HPV Vaccine Reduced Cervical Cancer Rates By 87%, UK Researchers Find

Researchers in the UK have reported a steep drop in the number of Cervical cancer cases among women and girls who were vaccinated.

Unlike most other cancers, Cervical cancer is caused by a virus named Human Papilloma Virus and the researchers have finally taken a huge leap ahead in treating the cancer. Published in The Lancet medical journal on Thursday, the result of the research indicated that women who were jabbed against HPV between ages of 12 and 13 with a GlaxoSmithKline's (GSK) Cervarix, were at an 87 percent lower risk of being affected by the virus against unvaccinated women.
Professor Peter Sasieni, one of the researchers at King's College, London, exclaimed that this revelation is supposed to have a huge impact on the field of treatment. The study has already linked the prevention of 450 cancers and 17,200 pre-cancers due to the vaccination drive. However, Dr. Sasieni implied that these numbers do not depict the true extent of the effect. Co-author of the study, Kate Soldan of the UK Health Security Agency said, "We hope that these new results encourage uptake as the success of the vaccination program relies not only on the efficacy of the vaccine but also the proportion of the population vaccinated."

The 13 year-long study, spanning from January 2006 to June 2019, used data funded by the Cancer Research UK, showed that the screening process had detected 28,000 cases of cervical cancer and 300,000 cases of cervical intraepithelial neoplasia (CIN3), the pre-cancer stage, in the country.

Among them, 450 cases of cancer and 17,000 cases of CIN3 have been reduced. GSK's Ceravix was first introduced in 2008 and it can protect the vaccinated individual against 70% to 80% of Cervical cancer variants. But in 2012, the drug was replaced by Merck & Co's Gardasil, which also protects against HPV which affects the head and neck.

For comments and feedback contact: editorial@rttnews.com

Health News

Follow RTT